60results about How to "Reduce transcription" patented technology

Disclosed herein are in vitro assays for the identification of interactions between proteins or other molecules, the identification of transcriptional activator proteins, and the detection of compounds that inhibit protein / protein or protein / compound interactions. Also disclosed herein are in vitro assays for the selection of interacting proteins and transcriptional activator proteins out of libraries.

There is disclosed a method of producing isobutanol. In an embodiment, the method includes providing a microorganism transformed with an isobutanol producing pathway containing at least one exogenous gene. The microorganism is selected to produce isobutanol from a carbon source at a yield of at least 10 percent theoretical. The method includes cultivating the microorganism in a culture medium containing a feedstock providing the carbon source, until isobutanol is produced. The method includes recovering the isobutanol. In one embodiment, the microorganism is a yeast with a Crabtree-negative phenotype. In another embodiment, the microorganism is a yeast microorganism with a Crabtree-positive phenotype. There is disclosed a microorganism for producing isobutanol. In an embodiment, the microorganism includes an isobutanol producing pathway containing at least one exogenous gene, and is selected to produce a recoverable quantity of isobutanol from a carbon source at a yield of at least 10 percent theoretical.

Antisense oligonucleotides specific for mammalian ACE mRNA have been identified. Administration of these oligonucleotides to animals resulted in a decrease in blood pressure, but no significant change in heart rate. Methods for discovering other oligonucleotides with the same activity are taught, as are uses of the antisense molecules for treatment of human and animal diseases.

The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and / or an uracile and / or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably RNAse H substantially independent and being complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a method of treatment for cis-element repeat instability associated genetic disorders. The invention also pertains to a modified oligonucleotide which can be applied in a method of the invention to prevent the accumulation and / or translation of repeat expanded transcripts in cells.

The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and / or autoimmune disorders.

The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and / or an uracile and / or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably RNAse H substantially independent and being complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a method of treatment for cis-element repeat instability associated genetic disorders. The invention also pertains to a modified oligonucleotide which can be applied in a method of the invention to prevent the accumulation and / or translation of repeat expanded transcripts in cells.

The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and / or autoimmune disorders.

The invention involves a method for modulating leukocyte activity, comprising delivering to a leukocyte a vector containing nucleic acid molecule(s), whereby the leukocyte contains Cas9 and the vector expresses one or more RNAs to guide the Cas9 to introduce mutations in one or more target genetic loci in the leukocyte, thereby modulating expression of one or more genes expressed in the leukocyte. The invention also involves identifying genes associated with leukocyte responses and experimental modeling of aberrant leukocyte activation and diseases associated with leukocytes by introducing mutations into leukocytes. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate leukocyte associated diseases.

The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and / or autoimmune disorders.

A method for producing a T cell having tolerance to an allergen or antigen which method comprises incubating the T cell with an antigen presenting cell (APC) in the presence of (i) a composition capable of upregulating expression of an endogenous Notch ligand in the APC and (ii) the allergen or antigen is provided.

The present invention provides an isolated promoter or an active fragment or derivative thereof capable of conferring selective expression on a gene to which it is operably connected in the endosperm of a developing plant seed and preferably in the basal endosperm transfer layer (BETL) of endosperm. The present invention also provides expression vectors and constructs and transgenic plant cells, plant parts and whole plants comprising the promoter, active fragments and derivatives, and well as methods of modulating one or more plant phenotypes employing the promoter, active fragments and derivatives.

The current methods and compositions provide for nucleotide sequences of promoters from Yarrowia lipolytica which may be used to drive gene expression in a cell. In some aspects, the promoters are useful for modulating lipid production in oleaginous organisms such as yeast.

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and / or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and / or the amount of IκB is materially unaltered.

Mutations in keratin genes or the genes that regulate keratin expression can result in epithelial cells lacking sufficient structural integrity. The resulting disruption of connective tissue gives rise to inherited disorders such epidermolysis bullosa. It has been found that various cannabinoids (including mixtures of cannabidiols and cannabinol) upregulate expression of various keratins such that loss of function in other keratin genes may be compensated for. By way of this upregulation, these cannabinoids can be used to treat epidermolysis bullosa and other connective tissue disorders arising from intermediate filament dysfunction.

The present invention relates to the treatment and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for reducing production of β amyloid by reducing or preventing the binding of amyloid precursor protein (APP) to an X11 adaptor protein. Also provided are methods for identifying molecules that modulate APP-X11 binding.

The present invention relates to a plant belonging to the Solanaceae family wherein said plant comprises a genetic trait providing Phytophthora resistance and wherein said resistance trait is encoded by a combination of at least two genes having a reduced expression, or transcription, of said genes or a reduced activity of proteins encoded by said genes as compared to said plant belonging to Solanaceae family being susceptible to Phytophthora.

It is an object of the present invention to provide: a dry analytical element for analyzing pancreatic lipase wherein the triglyceride is not transcribed on the support to contaminate a transportation slip or other analytical elements and wherein an additive solution of the triglyceride neither reaggregates nor precipitate, so that the dry analytical element is stable and is compatible with production. The present invention provides a dry analytical element for measuring pancreatic lipase contained in body fluid, which comprises triglyceride of long chain alkyl fatty acid having 12 to 22 carbon atoms, monoglyceride lipase, and a glycerin measurement reagent, and which comprises a water-impermeable support and at least one spreading or reagent layer, wherein a hydrophilic polymer at a weight ratio of 1.8:1 or greater with respect to the triglyceride is contained.

The present invention provides methods and compositions for said inhibition of drug resistance. In one embodiment, said invention provides methods and compositions for said inhibition of antibiotic resistance. The invention generally involves said administration of achaogens, agents that inhibit said mutational process, to inhibit said evolution of drug resistance. Also, described herein are compositions that are suitable for use as achaogens.

The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and / or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and / or the amount of IκB is materially unaltered.

The present invention relates to a plant belonging to the Solanaceae family wherein said plant comprises a genetic trait providing Phytophthora resistance and wherein said resistance trait is encoded by a combination of at least two genes having a reduced expression, or transcription, of said genes or a reduced activity of proteins encoded by said genes as compared to said plant belonging to Solanaceae family being susceptible to Phytophthora.

The polypeptide Fortilin (also known as Translationally Controlled Tumor Protein, TCTP) specifically interacts with p53, a tumor suppressor involved in the induction of apoptosis and the normal growth regulation of a cell. Fortilin also specifically binds MCL1 (Myeloid Cell Leukemia 1). Fortilin has the ability to prevent apoptosis, which may be unregulated in hyperproliferative cells. The present invention is directed at compositions and methods involving a Fortilin modulator, which can induce apoptosis, for the prevention, treatment, or diagnosis of hyperproliferative diseases and conditions, including cancer and atherosclerosis. It is directed also at compositions and methods involving Fortilin, which can inhibit apoptosis, for the treatment of diseases and condition characterized by apoptosis, including certain vascular conditions.

The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain of Shigella flexneri containing an inactivated ospF gene is also provided.

The invention provides application of a gene segment of a jasmonic acid-isoleucine hydroxylase encoding gene StCYP94B3-like and a silent vector of the gene segment in increasing the yield of potatoesand relates to the technical field of gene engineering. The cDNA (complementary desoxyribonucleic acid) sequence of the gene segment of StCYP94B3-like is shown in SEQ ID NO.1 in the description. Afterthe RNAi (ribonucleic acid interfere) silent vector is constructed by using the StCYP94B3-like gene segment and transformation of the silent vector into potatoes, the content of jasmonic acid-isoleucine (JA-Ile) can be remarkably increased, the content of jasmonic acid (JA) is not largely affected, and furthermore, the yield of the potatoes can be increased.

The invention discloses application of an asparagus extract in preparing a medicine for treating inflammation, and particularly relates to application of the asparagus extract in preparing a medicinefor treating vascular smooth muscle cell inflammation. The asparagus extract can also be used to prepare a medicine for treating diseases associated with the inflammation, including hypertension, atherosclerosis, coronary heart disease, myocardial infarction, cerebral apoplexy, and the like. The invention also provides the medicine for treating inflammation, and the medicine is prepared from the asparagus extract and a pharmaceutically acceptable carrier or auxiliary material. Active ingredients are extracted from asparagus, and the above application can be realized and has important medical and economic significance.

The invention provides a pressing plate state monitoring system assisting in filling of operation tickets. The system comprises a background host, a display screen device before a relay protection screen and a WiFi router, wherein the display screen device before the relay protection screen is connected with the background host through the WiFi router; the display screen device before the relay protection screen comprises a display screen and a power supply; the display screen is hung on a printer box panel in front of the relay protection screen, only information of the screen is displayed, and the display screen is in a standby dormant state for a long time; and the WiFi router is installed at the central position of a master control room and a relay protection room area, and a local area network of all the display screen devices before the relay protection screen and the background host is built.

The invention discloses an application of methyllycaconitine or citrate thereof in prevention or treatment of HIV related neurocognitive dysfunction. Wherein the use dosage of the methylethylenediamine or the pharmaceutically acceptable salt thereof is 1 nM to 1000 nM. The inventor finds that methyllycaconitine or citrate thereof can effectively inhibit alpha7nAChR activation, improve inflammation and cell injury induced by gp120, relieve brain tissue injury and improve cognitive disorder caused by HAND, so that the methyllycaconitine or citrate thereof has the effect of remarkably improving HAND symptoms concurrent by HIV, and a new target and a new way are provided for clinical treatment of HAND.

The present invention relates to a non-human transgenic mammal whose genome comprises: i) a first transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding a rotavirus protein selected from VP2, VP4, VP6 and VP7 and wherein said cDNA comprises a secretion signal sequence; ii) at least a second transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding another said rotavirus protein and wherein said cDNA comprises a secretion signal sequence; and wherein said rotavirus proteins are secreted separately and auto-assembled in milk in rotavirus like particles (VLP) or aggregates of said rotavirus proteins.

The present disclosure relates to a soybean plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, wherein the soybean plant has a reduced level, reduced activity or complete absence of DMR6 protein as compared to a soybean plant that is not resistant to the said pathogen, in particular organisms of the kingdom Fungi or the phylum Oomycota. The present disclosure further relates to a method for obtaining a soybean plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, comprising reducing the endogenous level or activity of DMR6 protein in the soybean plant. In addition, the present disclosure relates to the use of a DMR6 promoter for providing disease resistant soybean plants.

Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment. The new use of the CUEDC2 protein provides a new basis for determining a dosage regimen of adjuvant therapy after surgical operation of the breast cancer patients, thereby improving the therapeutic effect of the anti-cancer drugs and alleviating the suffering and economic burden of the patients.